Virus News and Research

Latest Virus News and Research

Intercell AG's revenues for full year 2009 increase 10.6%

Today, the biotech-vaccine company Intercell AG announced its financial results for Q4 and the preliminary results for the full financial year 2009, and presented an update on the Company's development programs.

2 Mar 2010

Inovio Biomedical's SynCon preventive DNA vaccine receives approval in Korea for Phase I clinical trial

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that its affiliate VGX International Inc. has received approval in Korea to begin a Phase I clinical trial in healthy volunteers for Inovio’s SynCon™ preventive DNA vaccine (VGX-3400) targeting H5N1 avian influenza.

2 Mar 2010

Most strains of pandemic H1N1 flu virus resist Tamiflu, say scientists

If the behavior of the seasonal form of the H1N1 influenza virus is any indication, scientists say that chances are good that most strains of the pandemic H1N1 flu virus will become resistant to Tamiflu, the main drug stockpiled for use against it.

2 Mar 2010

Merck's Isentress HIV/AIDS drug pricing: CalSTRS and CalPERS express concern

Today AIDS Healthcare Foundation (AHF) announced that the two largest public pension funds in the nation, the California State Teachers' Retirement System (CalSTRS) and the California Public Employees’ Retirement System (CalPERS), have sent letters to Merck and Co. Pharmaceuticals expressing concern over the company’s pricing for its key HIV/AIDS drug, Isentress—now the most expensive first-line AIDS treatment in the U.S.

2 Mar 2010

Study finds most HIV prevention, treatment, care efforts overlook IDUs

A systematic review of HIV prevention, treatment and care for injecting drug users (IDUs) throughout the world, published Monday in the journal Lancet, found that international efforts to fight the disease are largely overlooking this population, the Australian Associated Press/Sydney Morning Herald reports (Rose, 3/1).

2 Mar 2010

Joint Chiefs Chair visits Haiti to examine aid response

Joint Chiefs of Staff Chair Mike Mullen, who is President Barack Obama's top military adviser, visited Haiti over the weekend to examine relief and rebuilding efforts and meet with local leaders, Agence France-Presse reports. It was his first visit to the country after the earthquake, according to AFP.

2 Mar 2010

McGill University and RI MUHC secure $300,000 CIHR grant to develop VLP vaccines

The Canadian Institutes of Health Research (CIHR) have awarded a $300,000 grant for research focusing on the nature of the immune response induced by the action mechanisms of plant-made Virus-Like Particles (VLP) to Dr. Louis Vezina, Chief Scientific Officer of Medicago and to Dr. Brian Ward and Dr. Ciriaco Piccirillo of the Research Institute of the McGill University Health Centre (RI MUHC) and McGill University.

1 Mar 2010

Reversing protein deficiency through gene therapy can improve SMA

Reversing a protein deficiency through gene therapy can correct motor function, restore nerve signals and improve survival in mice that serve as a model for the lethal childhood disorder spinal muscular atrophy, new research shows.

1 Mar 2010

Researchers find gene regulator that plays key role in DS-AMKL

Between 5 and 10 percent of babies with Down syndrome develop a transient form of leukemia that usually resolves on its own. However, for reasons that haven't been clear, 20 to 30 percent of these babies progress to a more serious leukemia known as Down syndrome acute megakaryoblastic leukemia (DS-AMKL), which affects the blood progenitor cells that form red blood cells and platelets.

1 Mar 2010

Widespread cases of flu plunge from 49 to zero

Normally, this is the peak period for the flu in the United States. But that just doesn't seem to be the case this year.

27 Feb 2010

Fact-checks of the bipartisan health care summit

News outlets fact-check the bipartisan health care summit and provide analyses of the messaging and poll numbers lawmakers used during the six-hour event.

27 Feb 2010

UCLA School of Nursing selects CytoCore's PadKit Collection Kit for comparative cytology study of cervical cancer

CytoCore Inc., the developer of cost-effective products used in the practice of cytology for the detection and diagnosis of cancer and cancer related diseases, announced today that PadKit® Collection Kit, a transport kit using an intralabial device for the collection of gynecological samples, has been selected by the UCLA School of Nursing as the sample collection system for a comparative cytology study of cervical cancer.

26 Feb 2010

Cause of multiple sclerosis: Researchers test autoimmune hypothesis

A non-pathogenic bacterium is capable to trigger an autoimmune disease similar to the multiple sclerosis in the mouse, the model animal which helps to explain how human diseases work. This is what a group of researchers from the Catholic University of Rome, led by Francesco Ria (Institute of General Pathology) and Giovanni Delogu (Institute of Microbiology), have explained for the first time in a recently published article on the Journal of Immunology.

26 Feb 2010

MetLife Foundation Awards for Medical Research in Alzheimer's Disease: Four scientists honored

Complementary approaches to Alzheimer's research were recognized as four scientists received the prestigious MetLife Foundation Awards for Medical Research in Alzheimer's Disease in Washington, D.C.

26 Feb 2010

Regulus Therapeutics, GSK announce new collaboration on microRNA therapeutics targeting microRNA-122

Regulus Therapeutics Inc. today announced the establishment of a new collaboration with GlaxoSmithKline (GSK) to develop and commercialize microRNA therapeutics targeting microRNA-122 in all fields with Hepatitis C Viral infection (HCV) as the lead indication. Under the terms of the new collaboration, Regulus will receive additional upfront and early-stage milestone payments with the potential to earn more than $150 million in miR-122-related combined payments, and tiered royalties up to double digits on worldwide sales of products.

25 Feb 2010

CDC ACIP's vote for universal influenza vaccination recommendation: FFF endorses

Families Fighting Flu (FFF) fully supports today's vote by the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) to expand the current influenza vaccination recommendations to include all adults aged 19 to 49 years of age. Previous recommendations included all other age groups with the exception of this new adult population. This new recommendation will be implemented beginning with the 2010-2011 influenza season.

25 Feb 2010

α-defensins1-3 may be potential prophylactic agents in treatment of HIV / AIDS

HIV/AIDS remains one of the world's most significant public health challenges, particularly in developing countries. The Human Immunodeficiency Virus (HIV-1), the variant responsible for the pandemic, has the ability to infect different cell types such as T cells, macrophages and dendritic cells (DC). These latter cells are crucial in the defense against infectious agents and play a major role in viral pathogenesis.

25 Feb 2010

American Lung Association supports ACIP's recommendations for universal influenza immunization

The American Lung Association supports the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices' (ACIP) vote today that recommends universal influenza immunization with seasonal influenza vaccine.

25 Feb 2010

Chilean hospital's early use of antiviral treatment and aggressive measures helped reduce H1N1 cases

A Chilean hospital's early use of antiviral treatment in influenza patients and other aggressive measures helped reduce the number of severe H1N1 cases and related deaths. Those are the findings of a new study, now available online (http://www.journals.uchicago.edu/doi/abs/10.1086/650750), published in the March 15, 2010 issue of Clinical Infectious Diseases.

25 Feb 2010

Nevirapine taken to protect fetus from HIV should be avoided for one year after childbirth, say researchers

Women given the human immunodeficiency virus (HIV) prevention drug nevirapine to protect their fetus should not use an HIV-drug regimen that contains nevirapine for at least one year after childbirth, say researchers at the University of Alabama at Birmingham.

25 Feb 2010

Virus News and Research

Latest Virus News and Research

Intercell AG's revenues for full year 2009 increase 10.6%

Inovio Biomedical's SynCon preventive DNA vaccine receives approval in Korea for Phase I clinical trial

Most strains of pandemic H1N1 flu virus resist Tamiflu, say scientists

Merck's Isentress HIV/AIDS drug pricing: CalSTRS and CalPERS express concern

Study finds most HIV prevention, treatment, care efforts overlook IDUs

Joint Chiefs Chair visits Haiti to examine aid response

McGill University and RI MUHC secure $300,000 CIHR grant to develop VLP vaccines

Reversing protein deficiency through gene therapy can improve SMA

Researchers find gene regulator that plays key role in DS-AMKL

Widespread cases of flu plunge from 49 to zero

Fact-checks of the bipartisan health care summit

UCLA School of Nursing selects CytoCore's PadKit Collection Kit for comparative cytology study of cervical cancer

Cause of multiple sclerosis: Researchers test autoimmune hypothesis

MetLife Foundation Awards for Medical Research in Alzheimer's Disease: Four scientists honored

Regulus Therapeutics, GSK announce new collaboration on microRNA therapeutics targeting microRNA-122

CDC ACIP's vote for universal influenza vaccination recommendation: FFF endorses

α-defensins1-3 may be potential prophylactic agents in treatment of HIV / AIDS

American Lung Association supports ACIP's recommendations for universal influenza immunization

Chilean hospital's early use of antiviral treatment and aggressive measures helped reduce H1N1 cases

Nevirapine taken to protect fetus from HIV should be avoided for one year after childbirth, say researchers

A new way of characterising biomolecules eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in